Ovagen
Ovagen, a peptide. Synthetic tripeptide Glu-Asp-Leu from the Khavinson short-peptide programme, where each sequence is assigned to a tissue and proposed to act by…
Synthetic tripeptide Glu-Asp-Leu from the Khavinson short-peptide programme, where each sequence is assigned to a tissue and proposed to act by entering the nucleus and binding DNA to regulate gene expression. THE TISSUE ASSIGNMENT HERE IS DISPUTED BY THE LITERATURE: the peptide is marketed as a LIVER bioregulator, and every indexed study of it is RENAL — nephroprotection against gentamicin nephropathy and ischaemia/reperfusion injury in rats, with matrix metalloproteinase MMP-14 named as its target. The Khavinson liver preparation is a different thing entirely, the polypeptide complex Hepalin, which no source equates with this tripeptide.
PubChem CID 444128 (C15H25N3O8); Khavinson internal code T-35 (PMID:26033601, "Short peptides T-31 (AED) and T-35 (EDL)"). TWO FINDINGS THAT CONTRADICT THE VENDOR FRAMING, both worth keeping because the product is sold on the liver claim. (1) THE TISSUE IS WRONG. Every indexed EDL study is renal: PMID:28744634 verbatim, "EDL peptide produced a nephroprotective effect on experimental models gentamycin-induced nephropathy and ischemia/reperfusion kidney injury in rats", and PMID:24958378 names the target, "gelatinase MMP-14 is the target of T-35 peptide". The liver searches return nothing — `EDL tripeptide liver`, `Glu-Asp-Leu hepatocyte` and `hepatoprotective tripeptide Khavinson` are all zero hits. The Khavinson liver cytomedin is HEPALIN, listed as a separate preparation among the organ complexes (PMID:12096446, PMID:11213728) and never equated with this sequence. So systems[] says renal, and the marketed indication is recorded as vendor-asserted. (2) THE NAME COLLIDES WITH A VETERINARY DRUG. In PubMed, "Ovagen" is an ovine FSH superovulation preparation for sheep and goats, with real doses attached — "4.4 mg of Ovagen (n = 6) on day 3 of the estrous cycle" (PMID:20399062), "(Ovagen(TM), 0.44 iu/ml)" (PMID:18325004), also PMID:20036087, PMID:17126896, PMID:12785682. THOSE FSH DOSES MUST NEVER BE IMPORTED HERE. `Ovagen Khavinson` and `EDL Ovagen` both return zero, so nothing links the brand name to this sequence in the indexed literature either. TWO MORE SUBSTRING HAZARDS: "EDL" matches extensor digitorum longus muscle (43 hits, e.g. PMID:33540821), and "Glu-Asp-Leu" is contained in "Ala-Glu-Asp-Leu" (AEDL, bronchogen), a DIFFERENT tetrapeptide assigned to lung (PMID:22117547). MECHANISM: two docking papers from the same group DISAGREE about the DNA site — PMID:27909961 puts "peptides AEDL and EDL to ctcc sequence" while PMID:25946838 has AED and EDL forming "most energetically favorable complexes with d(ATATATATAT)2 sequences in minor groove of DNA". Both are recorded and neither is asserted; both are in-silico. The class claim that these peptides enter the nucleus and bind DNA has experimental support (PMID:22117547, FITC-labelled peptides imaged in HeLa nuclei) but NOT FOR THIS SEQUENCE — the peptides actually imaged were epithalon, pinealon, testagen and bronchogen, so the claim reaches EDL only by extrapolation.
Sources: PMID:28744634, PMID:24958378, PMID:26033601, PMID:27909961, PMID:25946838, PMID:30607912